Article: Judicialization of Zolgensma in the Ministry of Health: costs and clinical profile of patients

Objective: To investigate the costs and profile of patients who have filed a lawsuit against the Ministry of Health for the treatment of spinal muscular atrophy (SMA) with the onasemnogene abeparvovec (Zolgensma®).

Methods: This is a cross-sectional, descriptive study with a census design, based on records of lawsuits filed against the Ministry of Health between January 2019 and September 2022. Data was requested from the Ministry of Health via the Access to Information Act. Information was extracted on the epidemiological profile of the beneficiaries of the lawsuits, as well as the expenses spent by the Ministry of Health in cases where the requests were granted.

Results: 136 lawsuits were identified, of which 113 (83%) were favorable to patients at a cost of R$ 944.8 million in the period analyzed. Demographic (gender and age), clinical (SMA subtypes, use of ventilatory or nutritional support), and lawsuit (type of legal service) characteristics were not associated with the granting of lawsuits. Prior use of medication (nusinersena or ridisplam) was associated with the dismissal of lawsuits. Of the 113 lawsuits granted in favor of patients, only six (5.3%) would meet the criteria currently established by the National Committee for Health Technology Incorporation - Conitec (children up to six months without ventilatory and nutritional support). R$ 146 million was spent on supplying Zolgensma to children over the age of two, which is outside the recommendation contained in the drug's package leaflet.

Conclusions: The Ministry of Health incurs a high cost with the judicialization of Zolgensma for SMA, representing 2.45% of total spending on medicines in the Unified Health System, including spending by the three administrative spheres. Some of the lawsuits have been granted in disagreement with the criteria established by health technology assessment agencies and the drug manufacturer's recommendations.

Citing Articles

Spinal muscular atrophy in Brazil: from individual treatment to global management.

Servais L, Moreno C J Pediatr (Rio J). 2024; 101(1):4-6.

PMID: 39549722 PMC: 11763513. DOI: 10.1016/j.jped.2024.11.001.

References

1.

Chieffi A, Barata R . Legal suits: pharmaceutical industry strategies to introduce new drugs in the Brazilian public healthcare system. Rev Saude Publica. 2010; 44(3):421-8. DOI: 10.1590/s0034-89102010000300005. View

2.

Strauss K, Farrar M, Muntoni F, Saito K, Mendell J, Servais L . Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022; 28(7):1381-1389. PMC: 9205281. DOI: 10.1038/s41591-022-01866-4. View

3.

Verhaart I, Robertson A, Wilson I, Aartsma-Rus A, Cameron S, Jones C . Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017; 12(1):124. PMC: 5496354. DOI: 10.1186/s13023-017-0671-8. View

4.

Mendonca R, Matsui Jr C, Polido G, Serafim Silva A, Kulikowski L, Dias A . Intragenic variants in the gene determine the clinical phenotype in 5q spinal muscular atrophy. Neurol Genet. 2020; 6(5):e505. PMC: 7524579. DOI: 10.1212/NXG.0000000000000505. View

5.

Guimaraes R . New challenges in health technology assessment (HTA): the case of Zolgensma. Cien Saude Colet. 2023; 28(7):1881-1889. DOI: 10.1590/1413-81232023287.18122022. View

6.

Baioni M, Ambiel C . Spinal muscular atrophy: diagnosis, treatment and future prospects. J Pediatr (Rio J). 2010; 86(4):261-70. DOI: 10.2223/JPED.1988. View

7.

Day J, Finkel R, Chiriboga C, Connolly A, Crawford T, Darras B . Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021; 20(4):284-293. DOI: 10.1016/S1474-4422(21)00001-6. View

8.

Lin C, Kalb S, Yeh W . Delay in Diagnosis of Spinal Muscular Atrophy: A Systematic Literature Review. Pediatr Neurol. 2015; 53(4):293-300. DOI: 10.1016/j.pediatrneurol.2015.06.002. View

9.

Campolina A, Yuba T, de Soarez P . Decision criteria for resource allocation: an analysis of CONITEC oncology reports. Cien Saude Colet. 2022; 27(7):2563-2572. DOI: 10.1590/1413-81232022277.14242021. View

10.

Pera M, Coratti G, Berti B, DAmico A, Sframeli M, Albamonte E . Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?. PLoS One. 2020; 15(3):e0230677. PMC: 7089564. DOI: 10.1371/journal.pone.0230677. View

11.

Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C . Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021; 20(10):832-841. DOI: 10.1016/S1474-4422(21)00251-9. View

Judicialization of Zolgensma in the Ministry of Health: Costs and Clinical Profile of Patients